Leadership

Steven P. James

President and CEO

Michel Streuli, PhD

Senior Vice President, Research

Leonard Reyno, MD

Senior Vice President and Chief Medical Officer

Monte Montgomery

Senior Vice President and Chief Financial Officer

Kevin Baker, PhD

Senior Vice President, Preclinical Sciences and Program Management

Evan Greger

Vice President, Process Development and CMC

Mike Ellis, PhD

Vice President, Business Operations


Steven P. James

President and CEO

Steve has over 25 years of biopharma experience and has been involved in building and leading numerous companies. Prior to joining Pionyr in February 2016, he was president, CEO, and a director of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president, CEO, and a director of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics) and is currently chairman of Antiva Biosciences and a director of Allakos Inc., and Chrono Therapeutics. He is also a trustee of Middlebridge School in Rhode Island.

Michel Streuli, PhD

Senior Vice President, Research

Michel joined Pionyr Immunotherapeutics in 2016 to lead research. Prior to Pionyr, Dr. Streuli held senior research positions at Gilead, Merck, Schering-Plough, and Organon, following a decade on the faculties of the Dana-Farber Cancer Institute and Harvard Medical School. During his 16 years in the pharmaceutical and biotech industry, he has led numerous drug development programs from discovery through early clinical stage, with a focus on therapies for cancer, chronic viral, autoimmune and inflammatory diseases, including overseeing development of the immunomodulatory anti-PD-1 monoclonal antibody Keytruda, and chairing the Keytruda early development team that brought Keytruda to the clinic. Dr. Streuli holds a PhD degree from the University of Zurich, where he was involved in the cloning and characterization of interferon-alpha-2, which led to the development of INTRON A and PEG-INTRON.

Leonard Reyno, MD

Senior Vice President and Chief Medical Officer

Prior to joining Pionyr, Leonard Reyno was EVP and Chief Medical Officer at ORIC Pharmaceuticals leading the introduction of their first product candidate into human trials. Before that, he served as Senior Vice President and Chief Medical Officer at Agensys, a subsidiary of Astellas Pharma, where he led clinical stage development of multiple antibody products to novel targets through clinical proof of concept of multiple products. Dr. Reyno’s prior positions in industry included Global Medical Director for Taxotere/Breast cancer at Aventis, Medical Director and Lead Clinical Scientist for Herceptin at Genentech and Senior Director of Oncology at Cytokinetics. Before joining industry, Dr. Reyno was an academic oncologist, where he had both extensive experience as a clinician (especially in breast and genitor-urinary malignancy) as well as serving as Principal Investigator on multiple trials with the National Cancer Institute of Canada. Dr. Reyno was Head of Medical Oncology and the Oncology Clinical Research Unit at Dalhousie University from 1999- 2003, and previously Associate Professor of Medicine at McMaster University from 1993-1999.Dr. Reyno received his M.D. from McMaster University in 1986. He completed fellowships in internal medicine and medical oncology at McMaster and further training in drug development at the University of Maryland at Baltimore as the McEachern Fellow of the National Cancer Institute of Canada from 1991-1993. He has authored more than 25 scientific publications in major journals.

Monte Montgomery

Senior Vice President and Chief Financial Officer

Monte joined Pionyr Immunotherapeutics in August 2017 as Chief Financial Officer. Prior to Pionyr, Mr. Montgomery served as VP, Finance and Chief Accounting Officer at Relypsa, Inc. which was acquired by Galenica in September 2016. Prior to joining Relypsa, Mr. Montgomery was the Executive Director, Finance at KAI Pharmaceuticals where he oversaw Finance, Facility, Purchasing and IT activities until KAI’s acquisition by Amgen in July 2012. Before joining KAI, Mr. Montgomery was Director, SEC Reporting at Exelixis, Inc. where he was a key contributor in various equity offerings, collaborations, and other fund-raising activities. Earlier in his career, Mr. Montgomery was an audit professional in Ernst & Young life sciences practice. He holds a B.A. in Business Economics from the University of California, Santa Barbara and he is a certified public accountant (inactive).

Kevin P. Baker, PhD

Senior Vice President, Preclinical Sciences and Program Management

Dr. Baker joined Pionyr in 2018 to lead project management and nonclinical development. Kevin has over 30 years of research and development experience, including more than 25 years in the biopharmaceutical industry. Prior to joining Pionyr, he was Senior Vice President of Development Sciences at Five Prime Therapeutics, where he oversaw the nonclinical development and manufacturing for all of FivePrime’s clinical programs. Prior to FivePrime, Kevin was Associate Director at Human Genome Sciences (HGS) where he ran a research team focused on receptor-ligand interactions in the immune system, as well as the project team lead for Belimumab, a monoclonal antibody directed against BLyS/BAFF Belimumab is currently marketed for the treatment of SLE (lupus).

Prior to HGS, Kevin was a scientist leading a research lab in the molecular biology group at Genentech and was responsible for identifying, cloning and functional analysis of novel secreted proteins including receptor tyrosine kinases and DNases. Kevin holds a PhD in microbial genetics and molecular biology from the University of Dundee, Scotland, and performed postdoctoral studies in cell biology at the Biozentrum in the University of Basel, Switzerland.

Evan Greger

Vice President, Process Development and CMC

Evan joined Pionyr Immunotherapeutics in June2018 and has over 20 years of experience in leadership roles in biopharmaceutical companies, with research, process/product development, manufacturing, CMC, and regulatory expertise. Prior to Pionyr, he served as VP, CMC and Process Development for Cell Design Labs / Kite Pharma, where he worked on next generation CAR T therapy, and was the Senior Director, Manufacturing Process Sciences at Juno Therapeutics, where he advanced CAR T therapies into the EU with Celgene and into China with JW Therapeutics. Prior to this role, Evan was Global Head of Manufacturing Sciences and Technology for Biopharmaceutical Operations with Novartis in Basel, Switzerland. He previously held senior positions with Amgen, where he led Enbrel commercialization, advanced the oncology and biosimilar pipeline, and at Sanofi Pasteur and Alpharma, where he advanced vaccine development and commercialization. Evan holds an MBA from Seattle University and a MSc from University of Washington.

Mike Ellis, PhD

Vice President, Business Operations

Mike joined Pionyr in 2017 and has over 20 years of experience in innovative biopharmaceutical companies, with expertise in business and corporate development, alliance management, research and clinical development. Prior to Pionyr, he was with Regeneron’s Strategic Alliances group, where he led Regeneron’s broad antibody discovery alliance with Sanofi and managed key aspects of Regeneron’s PD-1 program, which formed the foundation of the comprehensive Regeneron-Sanofi immuno-oncology alliance. He was also a key contributor to numerous preclinical and clinical stage antibody programs across a variety of therapeutic areas. He previously held senior positions in corporate development at Renovis, and in research at Renovis, Exelixis and Mercator Genetics. Mike holds an MBA from the Wharton School of Business and a PhD from the University of California, Berkeley.